9 Citations (Scopus)
40 Downloads (Pure)


Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.

Original languageEnglish
Pages (from-to)383-389
Number of pages6
JournalMalaria Journal
VolumeVol. 16
Issue numbern.º 1
Publication statusPublished - 21 Sep 2017


  • Angola
  • Artemether-lumefantrine
  • CYP450
  • Human polymorphism
  • MDR1


Dive into the research topics of 'The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome'. Together they form a unique fingerprint.

Cite this